United Therapeutics (UTHR) Earnings Date, Estimates & Call Transcripts $372.89 +5.53 (+1.51%) (As of 11/22/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends United Therapeutics Latest Earnings SummaryUpcoming Q4 Earnings DateFeb. 19EstimatedActual EPS (Oct. 30) $6.39 Beat By $0.23 Consensus EPS (Oct. 30) $6.16 United Therapeutics released Q3 2024 earnings on October 30, 2024, reporting an EPS of $6.39, which topped the consensus estimate of $6.16 by $0.23. Quarterly revenue rose 22.9% year-over-year to $748.90 million, above analyst estimates of $722.62 million. With a trailing EPS of $22.77 and a P/E Ratio of 16.38, United Therapeutics' earnings are expected to grow 13.68% next year, from $25.22 to $28.67 per share. Conference Call TranscriptConference Call AudioEarnings Press ReleaseEarnings Slide DeckSEC 10-Q/10-K FilingUTHR Upcoming EarningsUnited Therapeutics' next earnings date is estimated for Wednesday, February 19, 2025, based off prior year's reporting schedules. Get United Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on United Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataUTHR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.UTHR Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Click play to stream The Final Frontier at no cost United Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242$5.10$5.93$5.52Q2 20243$5.55$6.50$5.92Q3 20243$5.69$7.41$6.33Q4 20242$6.04$7.83$6.94FY 202410$22.38$27.67$24.70Q1 20251$6.93$6.93$6.93Q2 20251$6.63$6.63$6.63Q3 20251$7.33$7.33$7.33Q4 20251$6.74$6.74$6.74FY 20254$27.63$27.63$27.63Q1 20261$6.42$6.42$6.42Q2 20261$6.47$6.47$6.47Q3 20261$7.15$7.15$7.15 United Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/19/2025(Estimated)------- 10/30/2024Q3 2024$6.16$6.39+$0.23$6.39$722.62M$748.90M 7/31/2024Q2 2024$6.33$5.85 -$0.48$5.85$691.87M$714.90M 5/1/2024Q1 2024$5.63$6.17+$0.54$6.17$620.31M$677.70M 2/21/2024Q4 2023$4.28$4.36+$0.08$4.36$575.01M$614.70M 11/1/2023Q3 2023$5.10$5.38+$0.28$5.38$585.82M$609.40M 8/2/2023Q2 2023$4.57$5.24+$0.67$5.24$524.18M$596.50M Coins Set to Soar with a Pro-Crypto White House (Ad)Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…Click here to reserve your free seat at the Crypto Community Summit5/3/2023Q1 2023$4.26$4.86+$0.60$4.86$514.37M$506.90M 2/22/2023Q4 2022$4.12$2.67 -$1.45$2.67$519.20M$491.50M United Therapeutics Earnings - Frequently Asked Questions When is United Therapeutics's earnings date? United Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 19th, 2025 based off last year's report dates. Learn more on UTHR's earnings history. Did United Therapeutics beat their earnings estimates last quarter? In the previous quarter, United Therapeutics (NASDAQ:UTHR) reported $6.39 earnings per share (EPS) to beat the analysts' consensus estimate of $6.16 by $0.23. Learn more on analysts' earnings estimate vs. UTHR's actual earnings. How can I listen to United Therapeutics's earnings conference call? The conference call for United Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read United Therapeutics's conference call transcript? The conference call transcript for United Therapeutics's latest earnings report can be read online. Read Transcript How can I view United Therapeutics's earnings report? United Therapeutics's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does United Therapeutics generate each year? United Therapeutics (NASDAQ:UTHR) has a recorded annual revenue of $2.33 billion. How much profit does United Therapeutics generate each year? United Therapeutics (NASDAQ:UTHR) has a recorded net income of $984.80 million. UTHR has generated $22.77 earnings per share over the last four quarters. What is United Therapeutics's price-to-earnings ratio? United Therapeutics (NASDAQ:UTHR) has a trailing price-to-earnings ratio of 16.38 and a forward price-to-earnings ratio of 14.79. The price/earnings-to-growth ratio is 1.08. What is United Therapeutics's EPS forecast for next year? United Therapeutics's earnings are expected to grow from $25.22 per share to $28.67 per share in the next year, which is a 13.68% increase. ` More Earnings Resources from MarketBeat Related Companies TEVA Earnings Results BPMC Earnings Results BHVN Earnings Results BBIO Earnings Results PRGO Earnings Results BHC Earnings Results ARWR Earnings Results ALNY Earnings Results BIIB Earnings Results INCY Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Nvidia’s world of pain awaits (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Click play to stream The Final Frontier at no cost This page (NASDAQ:UTHR) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredReality Check: Are You Prepared for What's Next?Global shifts, like the alliance of BRICS nations pushing for economic independence from the U.S. dollar, and ...Allegiance Gold | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
